TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22382664

Group type: EXPERIMENTAL
Intervention: low-DEX (loading, 3 μg/kg/h for 10 min; maintenance, 0.2 μg/kg/h for 60 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: moderate-DEX (loading, 6 μg/kg/h for 10 min; maintenance, 0.4 μg/kg/h for 60 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 20170790

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide-guided, intensive patient management (BM)
Number of subjects: 278
Study: 17590198

Group type: EXPERIMENTAL
Intervention: Topical mometasone furoate 0.1%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1%
Number of subjects: 20
Study: 15770966

Group type: EXPERIMENTAL
Intervention: Tc-99m DTPA after dehydration (urine specific gravity > 1.025)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tc-99m DTPA after adequate hydration (urine specific gravity < 1.010)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tc-99m MAG3 after dehydration
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tc-99m MAG3 after adequate hydration
Number of subjects: 11
Study: 11913292

Group type: EXPERIMENTAL
Intervention: Crest Professional Whitestrips system (14 contact hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nite White Excel 2 tray system (28 contact hours)
Number of subjects: 20
Study: 9618736

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (100 mg/kg b.w./24 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NAT2 genotype
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NAT2 phenotype
Number of subjects: 20
Study: 7621642

Group type: EXPERIMENTAL
Intervention: Light standard breakfast (Day A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heavy non‐standardized lunch (Day B)
Number of subjects: 10
Study: 2116316

Group type: EXPERIMENTAL
Intervention: Almitrine (100 mg oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6995131

Group type: COMPARATOR
Intervention: Clofibate 0.5 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bezafibrate 0.2 g
Number of subjects: 10
Study: 30730066

Group type: EXPERIMENTAL
Intervention: Caregiver burden measured by Zarit Burden Interview
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL) measured by EQ-5D-3L
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Satisfaction with services
Number of subjects: 1020
Study: 28430947

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Baseline ECG LVH
Number of subjects: 33357
Study: 26054890

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > 25)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Independent predictors of LVM
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Independent predictors of CMVR
Number of subjects: 208
Study: 23681371

Group type: EXPERIMENTAL
Intervention: Preservative free tafluprost 0.0015%
Number of subjects: 38

Group type: COMPARATOR
Intervention: Branded latanoprost 0.005%
Number of subjects: 38
Study: 21220660

Group type: COMPARATOR
Intervention: Basic Internet (BI)
Number of subjects: 2005

Group type: COMPARATOR
Intervention: Enhanced Internet (EI)
Number of subjects: 2005

Group type: EXPERIMENTAL
Intervention: Enhanced Internet plus telephone (EI+P)
Number of subjects: 2005
Study: 19266579

Group type: EXPERIMENTAL
Intervention: Bone-anchored hearing aid (BAHA)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Directional BAHA
Number of subjects: 7

Group type: COMPARATOR
Intervention: Omnidirectional BAHA
Number of subjects: 7
Study: 20021927

Group type: EXPERIMENTAL
Intervention: tirofiban (intravenous bolus 10 microg/kg followed by intravenous infusion of 0.15 microg/kg/min for 48 h)
Number of subjects: 157

Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 157
Study: 15817596

Group type: EXPERIMENTAL
Intervention: IDDS
Number of subjects: 143
Study: 11870140

Group type: EXPERIMENTAL
Intervention: Cytokine levels in pregnancies with fetal chromosomal abnormalities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytokine levels in euploid pregnancies (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of interleukin‐8 and interleukin‐6 levels
Number of subjects: 0
Study: 9871425

Group type: EXPERIMENTAL
Intervention: 200 mg quinidine premedication
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 10
Study: 7608829

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei subsp. casei strain GG (LGG)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: L. casei subsp. rhamnosus (Lactophilus)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of Streptococcus thermophilus and L. delbrückii subsp. bulgaricus (Yalacta)
Number of subjects: 49
Study: 2571860

Group type: EXPERIMENTAL
Intervention: CD45 monoclonal antibodies (mAbs) perfusion
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control human albumin solution
Number of subjects: 77
Study: 371293

Group type: EXPERIMENTAL
Intervention: Oral cholera chemical vaccine (2 tablets)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oral cholera chemical vaccine (3 tablets)
Number of subjects: 150
Study: 11603909

Group type: EXPERIMENTAL
Intervention: High pressure stent implantation (16-20 atm)
Number of subjects: 120
Study: 31434149

Group type: EXPERIMENTAL
Intervention: six-dose IV-TXA (total dosage more than 6 g)
Number of subjects: 175
Study: 31825973

Group type: EXPERIMENTAL
Intervention: Schizophrenia (SZ)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Obsessive-Compulsive Disorder (OCD)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: OCD
Number of subjects: 91
Study: 29339393

Group type: EXPERIMENTAL
Intervention: Finafloxacin (300 mg b.i.d. orally for uUTI and 800 mg q.d. i.v. for cUTI/PN)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Finafloxacin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg b.i.d. orally for uUTI and 400 mg b.i.d. i.v. for cUTI/PN)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 132
Study: 27369316

Group type: EXPERIMENTAL
Intervention: Sitting posture at baseline
Number of subjects: 240

Group type: COMPARATOR
Intervention: Face up lying down posture at baseline
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Eyes at a more downward angle
Number of subjects: 240
Study: 25355211

Group type: EXPERIMENTAL
Intervention: Normal sleep with therapeutic CPAP throughout
Number of subjects: 0

Group type: COMPARATOR
Intervention: REM disruption with CPAP reduced only in REM sleep
Number of subjects: 0
Study: 22507386

Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum OLB6378 (B. bifidum) administered within 48 hours of birth
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bifidobacterium bifidum OLB6378 (B. bifidum) administered more than 48 hours after birth
Number of subjects: 36
Study: 20674669

Group type: EXPERIMENTAL
Intervention: Biologic agents for treatment of rheumatic diseases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational cohorts and registries
Number of subjects: 0
Study: 17659971

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% every 10 minutes for one hour before surgery
Number of subjects: 27

Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3% every 10 minutes for one hour before surgery
Number of subjects: 27
Study: 16519103

Group type: EXPERIMENTAL
Intervention: Swim training for 7-8 years
Number of subjects: 1625

Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 1625
Study: 11826589

Group type: EXPERIMENTAL
Intervention: Education programs
Number of subjects: 0
Study: 10201739

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids pretreatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 14
Study: 7792280

Group type: EXPERIMENTAL
Intervention: Placental infarcts
Number of subjects: 50

Group type: COMPARATOR
Intervention: Positive controls (prolonged intrauterine death and fetal artery thromboses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Negative controls (uncomplicated pregnancies)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Internal negative control (non-infarcted tissue adjacent to infarcts)
Number of subjects: 50
Study: 2118853

Group type: EXPERIMENTAL
Intervention: rt-PA 100 mg (29.6-48.2 MU) administered over 90 min followed by intravenous heparin
Number of subjects: 0
Study: 360957

Group type: EXPERIMENTAL
Intervention: Carticaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both (Carticaine and Lidocaine)
Number of subjects: 120
Study: 30707938

Group type: EXPERIMENTAL
Intervention: Creatine before (CR-B)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Creatine after (CR-A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 39
Study: 30382900

Group type: EXPERIMENTAL
Intervention: 3D image fusion guidance
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard treatment without 3D image fusion guidance
Number of subjects: 106
Study: 27028014

Group type: EXPERIMENTAL
Intervention: Dermocosmetic product containing 20% azelaic acid, mandelic acid, phytic acid, 4N-butyl resorcinol, and ferulic acid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Other dermocosmetic products containing azelaic acid
Number of subjects: 60
Study: 24490942

Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 21912270

Group type: EXPERIMENTAL
Intervention: SyvekPatch NT plus manual compression
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: D‐Stat Dry plus manual compression
Number of subjects: 80

Group type: COMPARATOR
Intervention: manual compression alone
Number of subjects: 80
Study: 20074202

Group type: EXPERIMENTAL
Intervention: Adherence therapy intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication management training for mental health nurses
Number of subjects: 0
Study: 17342036

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography in small-size AVR group (n=17) with prosthetic aortic valves 21 mm; Peak pressure gradient at rest: 42.1 mm Hg, after dobutamine infusion: 85.1 mm Hg (P<0.05). Isovolumetric relaxation time returned to normal, significant decrease in left atrium and left ventricular diameters and volumes, LVMI decreased from 127.6±47.6 to 98.1±36.9.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography in large-size AVR group (n=13) with valves >21 mm; Peak pressure gradient at rest: 20.9 mm Hg, after dobutamine infusion: 54 mm Hg (P<0.05). LVMI decreased from 159.9±16.1 to 125.3±10.1.
Number of subjects: 30
Study: 16359289

Group type: EXPERIMENTAL
Intervention: Coronary sinus (CS) pacing for 20 minutes
Number of subjects: 21
Study: 11547472

Group type: COMPARATOR
Intervention: Intrathecal 0.3 mg morphine plus intravenous saline (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous 0.09 mg buprenorphine plus intrathecal saline (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg plus intravenous buprenorphine 0.09 mg (group 3)
Number of subjects: 30
Study: 9761043

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate (in males with severe head injury and traumatic subarachnoid hemorrhage)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Placebo (in males with severe head injury and traumatic subarachnoid hemorrhage)
Number of subjects: 1120
Study: 7570837

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine
Number of subjects: 96
Study: 3045264

Group type: EXPERIMENTAL
Intervention: Total abdominal radiotherapy (arm A) 2,250 rad in 20 fractions (107 patients)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Melphalan (arm B) 8 mg/m2/d X 4 every 4 weeks X 18 courses (106 patients)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chromic phosphate (arm C) 10 to 20 mCi (44 patients)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 257
Study: 31785015

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard of Care (Control)
Number of subjects: 220
Study: 30863027

Group type: EXPERIMENTAL
Intervention: Robotic fall prevention program (small robot-installed fall prevention software, personal coaching, and handbook)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Robotic fall prevention program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (received only handbook)
Number of subjects: 64
Study: 29079949

Group type: EXPERIMENTAL
Intervention: Dyadic Network Support Intervention (n=45)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Treatment as usual (Control, n=53)
Number of subjects: 98
Study: 25048751

Group type: EXPERIMENTAL
Intervention: Foley's catheter
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cook cervical ripening balloon
Number of subjects: 200
Study: 23188490

Group type: EXPERIMENTAL
Intervention: Asoprisnil (10 or 25 mg)
Number of subjects: 0
Study: 21478070

Group type: EXPERIMENTAL
Intervention: Carbosymag® (simethicone, activated charcoal, magnesium oxide)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 19738125

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/d) with gemcitabine (1,250 mg/m² days 1 and 8) and cisplatin (75 mg/m² day 1) or carboplatin (5 x AUC, day 1)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo with gemcitabine (1,250 mg/m² days 1 and 8) and cisplatin (75 mg/m² day 1) or carboplatin (5 x AUC, day 1)
Number of subjects: 154
Study: 16569567

Group type: EXPERIMENTAL
Intervention: Intercessory prayer (informed they may or may not receive prayer)
Number of subjects: 1802

Group type: COMPARATOR
Intervention: No intercessory prayer (informed they may or may not receive prayer)
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Intercessory prayer (informed they would receive prayer)
Number of subjects: 1802

Group type: COMPARATOR
Intervention: Control group (no intercessory prayer, uncertain)
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Intercessory prayer (certain of receiving prayer)
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: All groups (major events and 30-day mortality)
Number of subjects: 1802
Study: 12742844

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg of triamcinolone acetonide
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 11082826

Group type: EXPERIMENTAL
Intervention: 2‐mg nicotine gum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4‐mg nicotine gum
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0‐mg nicotine gum (placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 30
Study: 9165413

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (Paw) increased from 0 to 20 cm H2O during inspiratory hold maneuvers.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (Paw) at 20 cm H2O during inspiratory hold maneuvers.
Number of subjects: 14
Study: 8181594

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 200
Study: 2453596

Group type: EXPERIMENTAL
Intervention: Pyrazinamide (1500 mg for 2 months)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no pyrazinamide)
Number of subjects: 63
Study: 29334970

Group type: EXPERIMENTAL
Intervention: Digital media-based educational intervention conducted over two months using mail, Internet, and telephone platforms.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 360
Study: 26872868

Group type: COMPARATOR
Intervention: Traditional protocol (iopromide 370 mg/mL + 120 kV)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low tube voltage (100 kV), low contrast agent concentration (270 mg/mL), and iterative reconstruction
Number of subjects: 48
Study: 24611853

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Freedom from Smoking (FFS)
Number of subjects: 85
Study: 24330619

Group type: EXPERIMENTAL
Intervention: Cranberry beverage (450 ml daily for 10 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 45
Study: 20630440

Group type: EXPERIMENTAL
Intervention: GAITRite system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Stopwatch-footfall count technique
Number of subjects: 24
Study: 18522969

Group type: EXPERIMENTAL
Intervention: Brief GP training session (40-min training session on referral rationale and skills)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual care (referral guidance by post)
Number of subjects: 91
Study: 16361302

Group type: EXPERIMENTAL
Intervention: Gabapentin (1.2 g day(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo capsules)
Number of subjects: 40
Study: 11970774

Group type: EXPERIMENTAL
Intervention: Low identifiers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High identifiers
Number of subjects: 0
Study: 9620360

Group type: EXPERIMENTAL
Intervention: IFN-gamma (100 microg/day s.c. for 21 days)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 8929931

Group type: EXPERIMENTAL
Intervention: Grant Street Partnership (GSP) program
Number of subjects: 294

Group type: COMPARATOR
Intervention: Usual services group
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 294
Study: 1695778

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 320830

Group type: EXPERIMENTAL
Intervention: Pipamperone (80 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pipamperone
Number of subjects: 40
Study: 7151088

Group type: EXPERIMENTAL
Intervention: Intravenous tiapamil (1 mg/kg loading dose followed by 50 micrograms/kg/min infusion for 15 min)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous tiapamil (1.5 mg/kg loading dose followed by 75 micrograms/kg/min infusion for 15 min)
Number of subjects: 19
Study: 30614524

Group type: EXPERIMENTAL
Intervention: HPV self-testing
Number of subjects: 397
Study: 29360600

Group type: EXPERIMENTAL
Intervention: High-nitrate low-thiocyanate smoothie (∼4 mmol nitrate, ∼5 μmol thiocyanate)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-nitrate high-thiocyanate smoothie (∼4 mmol nitrate, ∼72 μmol thiocyanate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-nitrate low-thiocyanate smoothie (∼0.3 mmol nitrate, ∼5 μmol thiocyanate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-nitrate high-thiocyanate smoothie (∼0.3 mmol nitrate, ∼72 μmol thiocyanate)
Number of subjects: 11
Study: 27102891

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) administered 10 minutes before a meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pancreatic enzyme replacement therapy (PERT) administered 10 minutes after a meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PERT timing changed from after to before meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: PERT taken after the meal
Number of subjects: 18
Study: 24471786

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1386

Group type: COMPARATOR
Intervention: No Dexamethasone (Control)
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Non-Smokers (Control)
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Alcohol Abusers
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Non-Alcohol Abusers (Control)
Number of subjects: 1386
Study: 22260713

Group type: EXPERIMENTAL
Intervention: Running therapy (RT) or Nordic walking (NW) in addition to usual care, group-based, 1 hour session, two times a week for 6 months, increasing intensity.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low intensive non-aerobic exercises (Control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 19900312

Group type: EXPERIMENTAL
Intervention: Selective decontamination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 17983307

Group type: EXPERIMENTAL
Intervention: Made-in-the-U.S. scenario condition; European Americans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Made-in-Japan scenario condition; European Americans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Value orientation mediation; Study 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily event sampling study; Study 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional events congruent with personal values
Number of subjects: 0
Study: 15660541

Group type: COMPARATOR
Intervention: Placebo-controlled intervention
Number of subjects: 9
Study: 11930154

Group type: EXPERIMENTAL
Intervention: Upright fearful faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inverted faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face-specific N170 component
Number of subjects: 0
Study: 9817265

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (six cycles of cyclophosphamide, methotrexate, fluorouracil, and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No further treatment (observation group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (for patients with large tumors, both ER+ and ER-)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No further treatment (observation group for patients with large tumors, both ER+ and ER-)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-risk patients (ER+ tumors < 3 cm) monitored without therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premenopausal patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postmenopausal patients
Number of subjects: 0
Study: 7659764

Group type: EXPERIMENTAL
Intervention: Nicotine gum during week 1 post-cessation
Number of subjects: 215